Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

36.02 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 36.02
Bid (Size) 35.10 (1)
Ask (Size) 39.78 (1)
Prev. Close 36.02
Today's Range 36.02 - 36.02
52wk Range 32.44 - 78.58
Shares Outstanding 88,017,939
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga

Performance

YTD
+3.95%
+3.95%
1 Month
-8.56%
-8.56%
3 Month
+8.46%
+8.46%
6 Month
-35.71%
-35.71%
1 Year
-50.71%
-50.71%

More News

Read More
3 Beaten-Down Stocks That Could Soar This Year
Via The Motley Fool
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Analyst Ratings for Intellia Therapeutics
Via Benzinga
Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today?
Via InvestorPlace
Why Intellia Therapeutics Stock Jumped This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
Via Benzinga
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
Via InvestorPlace
Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Why Is Intellia Therapeutics Stock Trading Higher Today?
Via Benzinga
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Via Investor's Business Daily
Intellia Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
3 More Mid-Cap Biotechs The Street Sees Doubling
Via MarketBeat
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Via The Motley Fool
Top CRISPR Stocks
Via Talk Markets
Earnings Scheduled For February 23, 2023
Via Benzinga
3 Deeply Undervalued Stocks That Could Double Your Money
Via The Motley Fool
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
Via The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Via Talk Markets
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.